Nishimoto, Yoshinori

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Neurology) (Shinanomachi)

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)

Profile Summary 【 Display / hide

  • Clinical research
    Keio University School of Medicine, Ethics Committee Approval Number:20221155
    「Clinical studies to elucidate the molecular mechanisms associated with the pathogenesis of amyotrophic lateral sclerosis (ALS) and to identify eff ective drug targets」(UMIN000051823)(ver 2.3/updated on July 6, 2023)

    Frontiers Editor Board member (Frontiers in Molecular Neuroscience journal)

Career 【 Display / hide

  • 2022.04
    -
    Present

    慶應義塾大学 医学部, 神経内科, 専任講師

  • 2020.04
    -
    2022.03

    慶應義塾大学医学部, 神経内科, 助教

  • 2018.04
    -
    2020.03

    慶應義塾大学医学部, 百寿総合研究センター, 特任助教

  • 2016.10
    -
    2018.03

    東京都済生会中央病院, 神経内科, 医員

  • 2016.08
    -
    2018.03

    慶應義塾大学 医学部, 生理学教室, 助教

display all >>

Academic Background 【 Display / hide

  • 2003.04

    Keio University Graduate School of Medicine, Internal Medicine, Neurology

    Graduate School, Graduated, Doctoral course

  • 1997.04

    Keio University, Shool of Medicine

    University, Graduated

Academic Degrees 【 Display / hide

  • MD, Keio University, Coursework, 2003.03

  • PhD, Keio University, Coursework, 2008.10

    Determination of editors at the novel A-to-I editing positions.

Licenses and Qualifications 【 Display / hide

  • 日本国 医師免許

  • 日本内科学会認定 総合内科専門医

  • 日本内科学会認定 認定内科医

  • 日本内科学会認定 指導医

  • 日本神経学会認定 神経内科専門医

display all >>

Matters concerning Career Achievements 【 Display / hide

  • 2023.01
    -
    Present

    臨床研究 承認番号:20221155 「筋萎縮性側索硬化症(ALS)の病態に関連する分子メカニズムの解明と効果的薬剤標的を同定するための臨床研究」

     View Details

    臨床研究
    慶應義塾大学医学部・病院 倫理委員会 承認番号:20221155
    「筋萎縮性側索硬化症(ALS)の病態に関連する分子メカニズムの解明と効果的薬剤標的を同定するための臨床研究」(第1.2版/2023年1月12日承認)

 

Research Areas 【 Display / hide

  • Life Science / Neurology

Research Keywords 【 Display / hide

  • 筋萎縮性側索硬化症 (ALS)

  • 神経変性疾患

  • 神経分子生物学

  • 神経再生医学

  • RNA/ノンコーディングRNA

display all >>

Research Themes 【 Display / hide

  • Establishment of full-care system for the patients with amyotrophic lateral sclerosis (ALS), 

    2003.04
    -
    Present

  • 筋萎縮性側索硬化症(ALS)の核酸医薬による分子標的療法の開発, 

    2010.07
    -
    Present

  • 次世代シークエンス技術を活用した認知症の遺伝的リスク算出法の確立, 

    2018.04
    -
    Present

  • 認知症のオンライン診療データを活用した自動病態評価技術の開発, 

    2020.07
    -
    Present

 

Books 【 Display / hide

  • 脳神経内科ゴールデンハンドブック (ALSほか運動ニューロン疾患 分担執筆)

    西本 祥仁, 南江堂, 2020.06

    Scope: 運動ニューロン疾患及び類縁疾患

  • Chapter I 高齢者社会の現状とフレイル・ロコモ・サルコペニアの意義 3.百寿とはどのような方か?

    西本祥仁, 新井康通, クリニコ出版, 2019.11

  • Drosophila Oogenesis: Methods and Protocols

    Shibata S, Murota Y, Nishimoto Y, Yoshimura M, Nagai T, Okano H, Siomi MC., 2015

    Scope: Immuno-Electron Microscopy and Electron Microscopic In Situ Hybridization for Visualizing piRNA Biogenesis Bodies in Drosophila Ovaries.

Papers 【 Display / hide

  • Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management

    Sho Shimohama, Toshiki Tezuka, Takahata Keisuke, Shogyoku Bun, Hajime Tabuchi, Morinobu Seki, Yuki Momota, Natsumi Suzuki, Ayaka Morimoto, Yu Iwabuchi, Masahito Kubota, Yasuharu Yamamoto, Yasunori Sano, Ryo Shikimoto, Kei Funaki, Yu Mimura, Yoshinori Nishimoto, Ryo Ueda, Masahiro Jinzaki, Jin Nakahara, Masaru Mimura, Daisuke Ito

    Neurology (Neurology)  100 ( 3 ) e264 - E274 2023

    Accepted,  ISSN  00283878

     View Summary

    Background and Objectives: Previous studies have evaluated the diagnostic effect of amyloid PET in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to evaluate the association of the combination of 2 PETs with changes in diagnosis, treatment, and management in a memory clinic cohort.Methods: All participants underwent amyloid [18F]florbetaben PET and tau PET using [18F]PI-2620 or [18F]Florzolotau, which are potentially useful for the diagnosis of non-Alzheimer disease (AD) tauopathies. Dementia specialists determined a pre- and post-PET diagnosis that existed in both a clinical syndrome (cognitive normal [CN], mild cognitive impairment [MCI], and dementia) and suspected etiology, with a confidence level. In addition, the dementia specialists determined patient treatment in terms of ancillary investigations and management. Results: Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n = 40], MCI [n = 25], AD [n = 20], and non-AD dementia [n = 22]). The etiologic diagnosis changed in 25.0% in the CN, 68.0% in the MCI, and 23.8% with dementia. Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia. Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups. Discussion: The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau PET has a strong impact on the changes in diagnosis and management in memory clinics. Classification of Evidence: This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.

  • “Missing-Piece” Sign with Dural Arteriovenous Fistula at Craniocervical Junction: A Case Report

    Toshiki Tezuka, Tomonori Nukariya, Masahiro Katsumata, Tsubasa Miyauchi, Daiki Tokuyasu, Shunpei Azami, Yoshikane Izawa, Narihito Nagoshi, Hirokazu Fujiwara, Katsuhiro Mizutani, Takenori Akiyama, Masahiro Toda, Jin Nakahara, Yoshinori Nishimoto*

    Journal of Stroke and Cerebrovascular Diseases (Journal of Stroke and Cerebrovascular Diseases)  32 ( 7 ) 107152 2023

    Last author, Corresponding author, Accepted,  ISSN  10523057

     View Summary

    Objectives: Spinal dural arteriovenous fistula (sDAVF) is a rare and often underdiagnosed spinal disease. Early diagnosis is required because the deficits are reversible and delays in treatment cause permanent morbidity. Although the abnormal vascular flow void is a critical radiographic feature of sDAVF, they are not always present. A characteristic enhancement pattern of sDAVF has been recently reported as the “missing-piece” sign which can lead to the early and correct diagnosis. Methods: We presented imaging findings, treatment decisions, and the outcome of a rare case of sDAVF, in which the “missing-piece” sign appeared atypical. Results: A 60-year-old woman developed numbness and weakness in her extremities. Spinal MRI revealed longitudinal hyperintensity in the T2-weighted image, extending from the thoracic level to medulla oblongata. At first, myelopathy with inflammation or tumor was suspected because of the lack of flow voids and vascular abnormalities in CT-angiography and MR-DSA. However, we administered intravenous methylprednisolone and her symptom got worse with the appearance of the “missing-piece” sign. Then, we successfully diagnosed sDAVF by angiography. The “missing-piece” sign was considered to derive from inconsistency of the intrinsic venous system of spinal cord, with the abrupt segments without enhancement. The same etiology was considered in our case. Conclusions: Detecting the “missing-piece” sign can lead to the correct diagnosis of sDAVF, even if the sign appeared atypical.

  • Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel

    Fujiwara S., Kosaka T., Nishimoto Y., Kamisawa K., Watanabe K., Baba Y., Takeda T., Matsumoto K., Oya M.

    Prostate (Prostate)   2023

    ISSN  02704137

     View Summary

    Background: Serum testosterone level is a potential prognostic marker for castration-resistant prostate cancer. However, its role as a prognostic marker in cabazitaxel chemotherapy remains unclear. This study aimed to elucidate the clinical significance of serum testosterone levels before cabazitaxel chemotherapy. Methods: This single-institution, retrospective study included 47 patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel therapy. Serum testosterone levels were measured before the initiation of cabazitaxel therapy. Results: Progression-free survival and overall survival (OS) were not significantly different between patients with high and low serum testosterone levels. Analysis of patients aged <70 years revealed that those with high serum testosterone levels (total testosterone level > 0.055 ng/mL) had significantly longer OS than those with low serum testosterone levels (total testosterone level < 0.055 ng/mL, p = 0.012). Multivariate analysis revealed that low serum testosterone levels (hazard ratio [HR] = 11.874, 95% confidence interval [CI] 2.076–67.953, p = 0.005) and high prostate-specific antigen levels (HR = 18.051, 95% CI 2.462–132.347, p = 0.004) in the pretreatment phase were independent prognostic factors for OS in patients receiving cabazitaxel therapy. Conclusions: Serum testosterone level may be a prognostic marker for cabazitaxel therapy in patients with mCRPC who are younger than 70 years, and high serum testosterone levels may lead to longer survival.

  • Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study

    Takashi Sasaki, Yoshinori Nishimoto, Takumi Hirata, Yukiko Abe, Nobuyoshi Hirose, Michiyo Takayama, Toru Takebayashi, Hideyuki Okano, and Yasumichi Arai.

    eLife   2023

    Accepted

  • Measurement of polydoctoring as a crucial component of fragmentation of care among patients with multimorbidity: Cross-sectional study in Japan

    Takayuki Ando, Takashi Sasaki, Yukiko Abe, Yoshinori Nishimoto, Takumi Hirata, Junji Haruta, Yasumichi Arai

    Journal of General and Family Medicine  2023

    Accepted

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 武田科学振興財団 医学系研究助成 (精神・神経・脳領域) 「核内非翻訳RNA制御によるALS患者由来運動ニューロン変性抑制の試み」

    2022

    Principal investigator

  • 文部科学省 科学研究費補助金 基盤研究(C) 「ALSゲノム編集マウスを用いたGC/UGリッチRNA配列での病態考察と治療法開発」

    2021.04
    -
    2025.03

    Research grant, Principal investigator

  • KGRI (Keio University Global Research Institute)スタートアップ研究補助 (KGRI startup award) 「オンライン診療を用いた認知症診療の有効性、安全性評価」

    2020.07
    -
    2022.03

    Research grant, Principal investigator

  • 日本学術振興会 海外特別研究員 「Investigating the regulatory function of the exosome complex in RNA metabolism a nd motor neuron disease」

    2014
    -
    2015

    Principal investigator

  • 日本ワックスマン財団 留学研究助成

    2013

    Research grant, No Setting

display all >>

Works 【 Display / hide

  • 朝日学生新聞連載コラム「からだの教室 -知識の玉手箱-」

    西本 祥仁

    朝日学生新聞 毎週金曜日 全26回, 

    2014.04
    -
    2014.09

    Other

Awards 【 Display / hide

  • Neurogenetics Editor’s Pick 2021 (Frontiers in Neurology)

    2021.08

    Type of Award: Honored in official journal of a scientific society, scientific journal

  • KGRI (Keio University Global Research Institute) Startup Award

    2020.06, Keio University Global Research Institute, 「オンライン診療を用いた認知症診療の有効性、安全性評価」

    Type of Award: Keio commendation etc.

  • Selected key poster (Harvard Stem Cell Institute Retreat)

    2016.05, 11th Annual Harvard Stem Cell Institute Malkin Retreat 2016, 「Altered tRNA metabolism links RNA Exosome deficiency with motor neuron disease」

  • Physician's Recognition Award

    2015.08, American Medical Association, 「Pediatric Advanced Care Team Rounds」

  • 日本学術振興会 海外特別研究員

    2014.08

    Type of Award: Other

display all >>

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2024

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2023

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2022

  • LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

    2021